Fig. 1: Efficacy data of the NIMBUS study. | Nature Communications

Fig. 1: Efficacy data of the NIMBUS study.

From: Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)

Fig. 1

A Waterfall plot showing change in diameter of target lesions in the full patient population after a median of 30.6 months of follow-up, excluding three unevaluable patients (N = 27). B Kaplan–Meier curves showing progression-free survival in the full population (N = 30), and D among patients with TMB < 14 mut/Mb and patients with TMB ≥ 14 mut/Mb; (N = 30); C Kaplan–Meier curves showing overall survival in the full population (N = 30), and E among patients with TMB < 14 mut/Mb and patients with TMB ≥ 14 mut/Mb (N = 30). P-values are from Log-Rank tests. F Swimmer plot showing time to response and duration of response among the full patient population (N = 30). CI confidence interval, HR hazard ratio, m months, mOS median overall survival, mPFS median progression-free survival, mut/Mb mutations per megabase of DNA, NA not applicable, NE not evaluable, OS overall survival, PD progressive disease, PFS progression-free survival, PR partial response, SD stable disease, TMB tumor mutational burden.

Back to article page